Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189
Jf. Simpson et al., Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189, J CL ONCOL, 18(10), 2000, pp. 2059-2069
Purpose: The identification of a subset of patients with axillary lymph nod
e-positive breast cancer with an improved prognosis would be clinically use
ful. We report the prognostic importance of histologic grading and prolifer
ative activity in a cohort of patients with axillary lymph node-positive br
east cancer and compare these parameters with other established prognostic
factors.
Patients and Methods: This Eastern Cooperative Oncology Group laboratory co
mpanion study (E4189) centered on 560 axillary lymph node-positive patients
registered onto one of six eligible clinical protocols. Flow cytometric (p
loidy and S-phase fraction [SPF]) and histopathologic analyses (Nottingham
Combined Histologic Grade and mitotic index) were performed on paraffin-emb
edded tissue from 368 patients. Results: Disease recurred in 208 patients;
in 161 (77%), within the first 5 years. Mitotic index and grade were associ
ated with both ploidy and SPF (P less than or equal to.01). Within the firs
t 5 years of follow-up, mitotic index (P =.004), grade (P =.004), ploidy (P
=.006), and SPF (P =.05) were associated with time to recurrence; there wa
s also a significant association with survival. The effect of mitotic index
was largely a result of the difference between 0 to 2 mitoses/10 high-powe
r fields (HPF; 5-year recurrence of 31%) and more than 2 mitoses/10 HPF (5-
year recurrence of 52%). The 0 to 2 mitoses/10 HPF group was independently
associated with improved prognosis at 5 years (P =.002) in regression model
s that included other standard prognostic factors.
Conclusion: A subset of axillary lymph node-positive patients with improved
prognosis may be identified using a lower (< 3 mitoses/10 HPF) mitotic cou
nt than is usually performed. J Clin Oncol 18:2059-2069. (C) 2000 by Americ
an Society of Clinical Oncology.